Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Modified Dose Escalation, Open Label Trial to Determine the Therapeutic Effect and Safety of INCB007839 Combined With Trastuzumab in Patients With Previously Untreated HER2 Positive Metastatic Breast Cancer

NCT00864175 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT00864175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00864175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Modified Dose Escalation, Open Label Trial to Determine the Therapeutic Effect and Safety of INCB007839 Combined With Trastuzumab in Patients With Previously Untreated HER2 Positive Metastatic Breast Cancer
Lead sponsor
Incyte Corporation
Phase
Phase 1/2
Overall status
Terminated
Start date
July 31, 2007
Completion date
October 31, 2011
Enrollment
68 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer